HLA-DR Antibody (L243) - Azide and BSA Free

Name: HLA-DR Antibody (L243) - Azide and BSA Free
Brand: Novus Biologicals
SKU: NBP2-80773
Price: 399 USD
Availability: InStock

Novus Biologicals | Catalog # NBP2-80773

Submit a review

Product Documents

View Available Conjugates View Available Formulations

100% Guarantee

Product Specifications
Scientific Data
Applications
Flow Cytometry
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Human, Baboon, Canine, Primate

Applications

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Western Blot, ELISA, Block/Neutralize, Flow Cytometry, Flow (Cell Surface), Dual RNAscope ISH-IHC, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation, Functional, In vitro assay, Electron Microscopy, CyTOF-ready

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2a Kappa Clone # L243

Format

Azide and BSA Free

View all HLA-DR Primary Antibodies »

Product Specifications

Immunogen

Human lymphoblastoid cell line (RPMI 8866).

Reactivity Notes

Predicted cross-reactivity with Chimpanzee, Baboon, Cynomolgus, Rhesus, Marmoset, Tamarin, Squirrel Monkey

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2a Kappa

Theoretical MW

28 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for HLA-DR Antibody (L243) - Azide and BSA Free

Western Blot: HLA-DR Antibody (L243)Azide and BSA Free [NBP2-80773]

Western Blot: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Analysis of human spleen (A) and human tonsil (B) tissue using HLA-DR antibody at 2 ug/mL. Image from the standard format of this antibody.

Immunohistochemistry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773]

Immunohistochemistry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Staining of HLA-DR in human spleen using DAB with hematoxylin counterstain. Image from the standard format of this antibody.

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773]

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Human peripheral blood lymphocytes stained with L243 PE Image from the standard format of this antibody.

Flow (Cell Surface): HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773]

Flow (Cell Surface): HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Analysis using the Azide Free version of NB100-77855. Staining of HLA-DR expression by 5x10^5 BDCM cells using 0.5 ug of (red) and 0.5 ug of isotype control (green). This antibody and an anti-mouse IgG PE conjugated secondary antibody were used.

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773]

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Analysis using the Alexa Fluor (R) 700 conjugate of NB100-77855. Staining of HLA-DR protein in human PBMCs using HLA-DR antibody [clone L243; conjugated to Alexa Fluor (R) 700] at 1:100 with 25 minutes incubation at 4C in 2% human serum, 0.5 mM EDTA in DPBS. Image from verified customer review.

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773]

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Analysis using the Biotin conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with biotinylated L243, followed by Sav-PE.

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773]

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Analysis using the DyLight 405 conjugate of NB100-77855. Staining of HLA-DR in human PBMCs using anti-HLA-DR antibody. Image from verified customer review.

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773]

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Analysis using the FITC conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with L243 FITC.

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773]

Flow Cytometry: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Analysis using the PerCP/Cy5.5 conjugate of NB100-77855. Staining of HLA-DR expression by 5x10^5 human PBMC using 10 uL (0.25 ug) of this antibody. Cell surface flow kit was used for this test. Left panel shows the monocyte gate, right panel shows the lymphocyte gate.

Dual RNAscope ISH-IHC: HLA-DR Antibody (L243) - Azide and BSA Free [NBP2-80773] - Formalin-fixed paraffin-embedded tissue sections of human metastatic tonsil were probed for HLA-DR mRNA (ACD RNAScope probe, catalog # 475891; Fast Red chromogen, ACD catalog # 322500). Adjacent tissue section was processes for immunohistochemistry using mouse monoclonal (Novus catalog # NB100-77855) at 1:50 dilution for 1 hour at room temperature followed by incubation with the anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Image from the standard format of this antibody.

View 7 more images

Applications for HLA-DR Antibody (L243) - Azide and BSA Free

Application

Recommended Usage

Block/Neutralize

reported in scientific literature (PMID 12874328)

ELISA

reported in scientific literature (PMID 11070170)

Electron Microscopy

reported in scientific literature (PMID 21660937)

Flow Cytometry

0.5 ug/10^6 cells

Functional

reported in scientific literature (PMID 17900279)

Immunocytochemistry/ Immunofluorescence

reported in scientific literature (PMID 7835916)

Immunohistochemistry

1:10 - 1:500

Immunohistochemistry-Frozen

1:10 - 1:500

Immunohistochemistry-Paraffin

1:100

Immunoprecipitation

1:10 - 1:500

In vitro assay

reported in scientific literature (PMID 19620786)

Western Blot

1:100 - 1:2000

Application Notes

It is recommended that the reagent be titrated for optimal performance for each application. This antibody is CyTOF ready.

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
Spillover Popups - Visualize the spectra of individual fluorochromes
Antigen Density Selector - Match fluorochrome brightness with antigen density

Build Your Panel Now

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: HLA-DR

Human Leukocyte Antigen -DR isotype (HLA-DR) is a major histocompatibility complex (MHC) class II molecule expressed by antigen presenting cells (APCs) that plays a significant role in immune response (1). Class II molecules also include isoforms HLA-DP and -DQ (1,2). These type I membrane glycoproteins on APCs present peptides to helper T cells and T cell receptors on CD4+ cells (1). In humans, the genes encoding class II MHC proteins are located on chromosome 6p21, where HLA-DR is typically the most highly expressed, followed by HLA-DQ and then HLA-DP (3). Structurally, HLA-DR molecules are heterodimers consisting of an alpha chain subunit with an approximate theoretical molecular weight of 34 kDa and one of many approximately 30 kDa beta subunits (1-3). The alpha and beta genes are considered highly polymorphic with duplication resulting in nine DRB (beta subunit of HLA-DR) genes (DRB1-DRB9); though only DRB1, DRB3, DRB4, and DRB5 are considered functional (2,3). On the other hand, the alpha subunit is encoded by a single DRA gene (2,3). Studies focusing on the structural and biochemical properties of peptides that bind to HLA-DR molecules have helped contribute to subunit vaccine design and development (3).

Given the role in adaptive immunity, HLA-DR allele polymorphisms, gene misexpression, and dysfunction has been implicated in many diseases ranging from autoimmune disorders to cancer (2). HLA-DR is also a classical biomarker for disease, including sepsis where reduced expression of HLA-DR molecules on monocytes, as measured by flow cytometry, indicates diagnosis and prognosis (4,5). Immunosuppression observed with sepsis results in decreased surface expression of HLA-DR and concurrent increase in expression of programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), and B and T lymphocyte attenuator (BTLA) (4). This altered expression results in poor T cell response and apoptosis, along with reduced interferon-gamma (IFN-gamma) production and increased pro-inflammatory cytokine release (4). Furthermore, the decrease in HLA-DR expression is also correlated with the decrease in CD14lowCD16+ inflammatory monocytes (5). Interestingly, COVID-19 patients also exhibit a reduction in HLA-DR that correlates with disease severity and immunosuppression (5).

References

1. Andersson G. (1998). Evolution of the human HLA-DR region. Frontiers in bioscience : a journal and virtual library. https://doi.org/10.2741/a317

2. Shiina, T., Hosomichi, K., Inoko, H., & Kulski, J. K. (2009). The HLA genomic loci map: expression, interaction, diversity and disease. Journal of human genetics. https://doi.org/10.1038/jhg.2008.5

3. Stern, L. J., & Calvo-Calle, J. M. (2009). HLA-DR: molecular insights and vaccine design. Current pharmaceutical design. https://doi.org/10.2174/138161209789105171

4. Zhuang, Y., Peng, H., Chen, Y., Zhou, S., & Chen, Y. (2017). Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis. Frontiers in bioscience (Landmark edition). https://doi.org/10.2741/4547

5. Benlyamani, I., Venet, F., Coudereau, R., Gossez, M., & Monneret, G. (2020). Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review. Cytometry. Part A : the journal of the International Society for Analytical Cytology. https://doi.org/10.1002/cyto.a.24249

Long Name

Major Histocompatibility Complex Class II DR

Alternate Names

HLA-DRA, HLADR, MHC Class II DR

Gene Symbol

HLA-DRA

Additional HLA-DR Products

Product Documents for HLA-DR Antibody (L243) - Azide and BSA Free

Download Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for HLA-DR Antibody (L243) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.